Merck expanded access program August 11, 1995 deadline.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D017320:HIV Protease Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D006297:Health Services Accessibility; D015277:Hotlines; D006801:Humans; D019469:Indinavir; D018579:Patient Selection; D010593:Pharmaceutical Services; D011725:Pyridines / Q000600:supply & distribution* / Q000627:therapeutic use; D012041:Regional Medical Programs
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D019469:Indinavir